CONGENITAL HEMOPHILIA B

Clinical trials for CONGENITAL HEMOPHILIA B explained in plain language.

Never miss a new study

Get alerted when new CONGENITAL HEMOPHILIA B trials appear

Sign up with your email to follow new studies for CONGENITAL HEMOPHILIA B, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 2 Not yet finished but already full! 1

New hemophilia drug hympavzi under safety watch

Disease control Ongoing

This study tracks the safety of Hympavzi (marstacimab) in 50 people with hemophilia A or B who do not have inhibitors. Participants receive weekly injections to help control bleeding. The main goal is to monitor any side effects in real-world use.

Matched conditions: CONGENITAL HEMOPHILIA B

Sponsor: Pfizer • Aim: Disease control

Last updated Jun 27, 2026 12:02 UTC

CONGENITAL HEMOPHILIA B

Get alerted when new CONGENITAL HEMOPHILIA B trials appear

New hemophilia drug hympavzi under safety watch